文档介绍：创新,全球化的动力
柯石谛
阿斯利康中国(含香港地区)总裁
交通大学
8 November 2003
创新–全球化的动力Innovation – the Driving Force behind Globalization
制药行业
The Pharma industry
制药行业的创新
Innovation in the pharma-industry
什么是全球化?
What is globalization?
国际企业中的领导力
Leadership in a pany
中国的制药行业
Pharma market in China
Q & A
创新和全球化Innovation and Globalization
创新和全球化是相互依存、相互促进的
Innovation and globalization are mutually dependent and enabling
只有不断创新的企业才能在全球获得成功
Only panies can essfully globalize
全球化的企业更能支付和回收越来越高的创新成本
panies are more able to afford and recover the higher and higher cost of innovation
创新
Innovation
全球化
Globalization
我们的目标Our Ambition
一个富于创新的、快速的和高效的公司,凭借其全球范围内的销售和市场方面的优势,充分挖掘并实现研发的巨大潜力,从而提供持续的、顶尖的财政增长。
A creative, fast and pany with the global sales and marketing strength to realize the full potential from productive R&D – thereby delivering sustainable top tier financial growth.
Sir Tom McKillop
CEO AstraZeneca
October 2003
阿斯利康工作重点AZ’ s Key Business Priorities
不断增加的鼓东利益
Increased Shareholder Value
快速、有效的组织机构
Fast anization
关键产品的增长
Growth through Key Products
全球范围的成功
Win Globally
顾客首选的合作伙伴
First Choice for Customers
源源不断的新产品
Secure Flow of New Products
建立人才储备
Build Talent Base
阿斯利康2002年关键的统计数据AstraZeneca 2002 Key Statistics
178亿的销售额
Sales of billion
营运利润44亿美元
Operating profit of $ billion
全球58000员工
58,000 employees worldwide
研发费用超过30亿–销售额的17%
R&D spend of more than 3 billion – 17% of sales
10 – 12 years to bring new medicine to market
在5个国家拥有9个大型研发中心
9 major R&D centers in 5 countries
在20个国家拥有34个生产基地
34 manufacturing facilities in 20 countries
顶级的销售队伍和广泛的分布:在美国超过6000名;美国之外超过14000名
Top echelon sales force size and reach; > 6,000 US reps; >14,000 outside US
到2006年全球制药市场的增长–美国是主要的增长点Global Growth to 2006 – Driven by the US
2001
2006
ROW
17%
USA
49%
Japan
15%
Top 5 Europe
19%
Top 5 Europe
17%
Japan
10%
ROW
14%
USA
59%
USD390 billion
USD630 billion
Pharma Market
对21世纪制药行业的新建议New Suggestions for the Pharma Industry in the 21st Century
在